Abstract Details

Title A Long-Term Analysis of Aspiration Pneumonia in Patients with Parkinson's Disease

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 144

Objective

Background BACKGROUND: PD is a neurodegenerative disease lacking a cure or neuroprotective treatment. As with all chronic diseases, the course of progression in PD is associated with complications. AsPna is amongst the leading causes of morbidity and mortality in PD patients. Understanding the risk and mortality trends overtime may increase awareness of this problem.

Design/Methods DESIGN/METHODS: The National Hospital Discharge Survey was used to identify percentage of PD patients with AsPna compared to non-PD patients, and their in-hospital mortality for years 1980-2010. Comparisons were made before and after exclusion of patients with: age ?50 years, stroke, amyotrophic lateral sclerosis, Alzheimers disease and atypical parkinsonism. Additional comparisons were made after dividing patients into age-quintiles (from age 50-95).

Results RESULTS: AsPna occurred in 245,087 (3.9%) of 6,268,447 PD patients and only 0.69% of 1,087,422,493 non-PD patients (relative risk 3.7). After excluding confounders, 3.77% vs. 1.02% had AsPna, respectively. Average mortality of PD patients was comparably less (17.9% vs. 22.7%). By age-quintiles (from age 50-95), over 31-years the highest percentage of AsPna was among 76-80 years, while over the past 5-years, an additional higher peak occurred at age 86-90 years. Similar comparison showed highest mortality in patients in their early-80s. Trends over 31-years reveal an increase in percentage of patients with AsPna among PD and non-PD groups with an associated decrease in mortality.

Conclusions CONCLUSIONS: Symptomatic treatment and prevention of complications is the mainstay of PD-management. Our analysis of a large-national database shows that PD patients live longer now than in the past and tend to have more AsPna but with lower mortality than non-PD patients. Further research should investigate interventions to curb the increase in AsPna.

Authors/Disclosures
Umer Akbar, MD PRESENTER	Dr. Akbar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LANGaware.
	No disclosure on file
Bhavpreet S. Dham, MD	No disclosure on file
Michael S. Okun, MD, FAAN (University of Florida)	Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��